

DRAFT Proposed Additions and Deletions to Appendix A of NIOSH Alert on Hazardous Drugs (April 6, 2009)		
Established Name	Proprietary Name	AHFS Pharmacologic-Therapeutic Classification
Additions to Appendix A		
Alafacet	Amevive®	84.92 Miscellaneous skin and mucous membrane agents
Bortezomib	Velcade®	10:00 Antineoplastic agents
Bosentan	Tracleer®	24:12.92 Vasodilating agents
Clofarabine	Clolar™	10:00 Antineoplastic agents
Dasatinib	Sprycel®	10:00 Antineoplastic agents
Decitabine	Dacogen™	10:00 Antineoplastic agents
Entecavir	Baraclude®	8:18.32 Antiviral Nucleocide
Infliximab	Remicade®	92:00 Biological Response Modifiers
Interferon beta 1a	Avonex®	92:00 Biological response modifiers
Interferon beta 1b	Betaseron®	92:00 Biological response modifiers
Lenalidomide	Revlimid®	92:00 Miscellaneous therapeutic agents
Medroxyprogesterone acetate	Depo-Provera®/Provera®	68:32 Progestins
Nelarabine	Arranon®	Not in AHFS
Palifermin	Kepivance™	84:16 Cell stimulants
Paroxetine HCl	Paxil®	28:16.04.20 Selective serotonin uptake inhibitors
Pemetrexed	Alimta®	10:00 Antineoplastic agents
Pentetate calcium trisodium	Pentetate Calcium Trisodium	Not in AHFS
Rasagiline mesylate	Azilect®	28:36 Antiparkinsonian agents
Risperidone	Respidal®/Respidal Consta®	28:16.08.04 Atypical antipsychotics
Sirolimus	Rapamune®	92:00 Immunosuppressive agents
Sorafenib	Nexavar®	10:00 Antineoplastic agents
Sunitinib malate	Sutent®	10:00 Antineoplastic agents
Vorinostat	Zolinza™	10:00 Antineoplastic agents
Zonisamide	Zonegran®	28:12.92 Anticonvulsant
Deletions to Appendix A		
Bacillus Calmette-Guerin (BCG)	Theracys®	80:12 Vaccines

Source: National Institute for Occupational Safety and Health, Washington, DC.